Peptides for muscle growth: an evidence ranking of what actually works

“Peptides for muscle growth” is one of the most confident corners of the bodybuilding internet and one of the least evidenced. The pitch is seductive: a few subcutaneous shots that raise growth hormone, speed recovery, and unlock lean mass the way the pros supposedly do it. Strip away the forum lore and grade these molecules by the only thing that matters — randomized human trials showing actual gains in muscle size or strength — and the picture collapses. Almost none of the peptides sold for physique have ever cleared that bar. The compound that demonstrably builds muscle in controlled trials is testosterone, which is not a peptide at all. This is an evidence ranking of what’s marketed, sorted by what the human data can actually support.

The grading rule: muscle is an outcome, not a lab value

Bodybuilding peptide marketing leans almost entirely on surrogate markers — a growth-hormone pulse, an IGF-1 bump, a faster-feeling recovery. Those are mechanism signals, not proof that a muscle got bigger or a lift got heavier. The honest test for any compound that claims to grow muscle is whether a randomized, controlled trial measured lean mass, cross-sectional area, or strength and found a real difference versus placebo. That bar is high on purpose, because it is exactly the bar testosterone clears and the marketed peptides do not. Below, the compounds are grouped by how close they get to it.

Tier 1 — Proven, but not a peptide: testosterone

The cleanest muscle-growth evidence in the entire conversation belongs to a steroid hormone, not a peptide. In a landmark randomized, placebo-controlled trial, supraphysiologic testosterone increased fat-free mass, muscle size, and strength in healthy men — and did so even in participants who weren’t training.^[1] That is what a real anabolic signal looks like in a trial: measured muscle, measured strength, against placebo. It is the reference standard the peptides are implicitly compared to in every “build muscle” ad, and none of them have produced anything like it. Testosterone is a controlled substance with its own risk profile and is prohibited in sport; the point here isn’t to endorse it but to mark where the evidentiary ceiling actually sits — far above any vial labeled “muscle peptide.”

Tier 2 — Biomarker only: the GH secretagogues

This is the heart of the muscle-peptide market: compounds that prod the growth-hormone axis — sermorelin and tesamorelin (GHRH analogs), the ipamorelin / CJC-1295 blend, GHRP-6 and hexarelin(ghrelin-mimetic GH-releasing peptides), and the oral ghrelin mimetic MK-677 (ibutamoren). They share one verified effect and one missing one. The verified effect: they raise growth hormone and IGF-1. Growth-hormone secretagogue treatment measurably lifts serum IGF-1 in men.^[2] The missing one: that a higher IGF-1 translates into bigger or stronger muscle in healthy, training adults. It mostly doesn’t, and the broader experience of stimulating the GH axis in adults has been underwhelming on body composition relative to its side-effect burden.^[3]

The same caveat governs the injectables. The single most rigorous randomized human study of ipamorelin tested it for an unrelated use — postoperative ileus after bowel surgery — and the peptide missed its primary endpoint,^[5] a reminder that “raises GH” doesn’t reliably convert into clinical results even where it has been formally studied. None of these peptides has a randomized trial showing added muscle or strength in healthy adults from GH-axis stimulation. For the molecule-level detail, see our reviews of sermorelin and the ipamorelin & CJC-1295 blend. Worth stating plainly: GH secretagogues are prohibited at all times under the WADA code, so for any tested athlete this tier is off the table regardless of the evidence.

Tier 3 — Animal data only: BPC-157 and TB-500

The “recovery” peptides are sold to muscle-builders on an indirect logic: heal connective tissue faster, train harder, grow more. BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) dominate this tier. The honest status is that their tendon-, muscle-, and ligament-repair stories rest almost entirely on rodent and in-vitro work — there are essentially no controlled human trials demonstrating they accelerate recovery, let alone build muscle, in people. They surface in physique marketing for the same reason they surface in every vendor’s catalog — ubiquity, not because any human muscle data backs them. Our BPC-157 evidence review and TB-500 / thymosin beta-4 review walk through exactly how thin the human side is. Both are unapproved for any such use, and thymosin beta-4 is on the WADA prohibited list.

Tier 4 — Potent in theory, untested and banned: IGF-1 LR3 and follistatin

The final tier is where the marketing gets boldest and the evidence gets thinnest. IGF-1 LR3is a long-acting analog of insulin-like growth factor-1 — the very hormone GH secretagogues are trying to raise indirectly — sold as a direct anabolic shortcut. Follistatin (and follistatin gene and peptide products) targets myostatin, the brake on muscle growth, on the theory that releasing the brake unlocks hypertrophy. Both are genuinely potent biology. Neither has the human data to match: there are no randomized controlled trials establishing that injectable IGF-1 LR3 or over-the-counter follistatin products safely build muscle in healthy adults. They are unapproved, sold as “research” material of unverified content, carry serious theoretical risks (IGF-1 signaling and cancer biology among them), and are prohibited under the WADA code (IGF-1 and its analogs as growth factors; myostatin inhibitors explicitly). “Powerful mechanism, zero human outcome trials, banned in sport” is the whole story.

The GLP-1-era lesson: a moved biomarker is not a result

There’s a useful parallel from the weight-loss world. For years, plenty of compounds could nudge a metabolic lab value without moving the scale in a trial; then the incretin drugs arrived and showed what an actual outcome looks like — double-digit percentage weight loss in randomized studies, not a hopeful marker (we cover that sort in peptides for weight loss: the evidence). Muscle peptides are stuck at the stage incretins left behind: they can move IGF-1, they can move a body-composition readout, but the randomized proof of bigger, stronger muscle in healthy adults hasn’t arrived. Until it does, a raised IGF-1 is a promise, not a payoff.

So what actually builds muscle?

The unglamorous answer is the one with the trials behind it: progressive resistance training and adequate protein do the heavy lifting, and the only injectable with randomized muscle-and-strength data is testosterone — a controlled, banned-in-sport hormone, not a wellness peptide. The peptides marketed for physique range from biomarker-movers (GH secretagogues) to animal-data hopefuls (BPC-157, TB-500) to untested, banned long-shots (IGF-1 LR3, follistatin). If you’re evaluating one anyway, anchor the decision to evidence rather than forum consensus: our peptide evidence matrix grades each molecule, the peptide therapy cost guide shows what each route really charges, and the peptide therapy provider comparison covers the legitimate telehealth options on care model and price.

The honest bottom line

If “best peptides for muscle growth” brought you here, the evidence-first answer is uncomfortable: none of the peptides sold for muscle has randomized human proof of bigger or stronger muscle in healthy adults. GH secretagogues move a biomarker; BPC-157 and TB-500 are animal stories; IGF-1 LR3 and follistatin are potent-but-untested and banned. The one molecule with real muscle data is testosterone, and it’s not a peptide. Grade every vial by the same question — where is the randomized human trial? — and the marketing falls away from the medicine.